DE69428536T2 - A3 ADENOSINE RECEPTOR AGONISTS - Google Patents

A3 ADENOSINE RECEPTOR AGONISTS

Info

Publication number
DE69428536T2
DE69428536T2 DE69428536T DE69428536T DE69428536T2 DE 69428536 T2 DE69428536 T2 DE 69428536T2 DE 69428536 T DE69428536 T DE 69428536T DE 69428536 T DE69428536 T DE 69428536T DE 69428536 T2 DE69428536 T2 DE 69428536T2
Authority
DE
Germany
Prior art keywords
receptor
adenosine receptor
mammal
uronamide
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69428536T
Other languages
German (de)
Other versions
DE69428536D1 (en
Inventor
A Jacobson
Carola Gallo-Rodriguez
Galen J Van
Lubitz K Von
Kim Jeong
- Kr Seoul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
National Aeronautics and Space Administration NASA
Original Assignee
US Department of Health and Human Services
National Aeronautics and Space Administration NASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, National Aeronautics and Space Administration NASA filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69428536D1 publication Critical patent/DE69428536D1/en
Publication of DE69428536T2 publication Critical patent/DE69428536T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

The present invention provides N6-benzyladenosine-5'-N-uronamide and related substituted compounds, particularly those containing substituents on the benzyl and/or uronamide groups, and modified xanthine ribosides, as well as pharmaceutical compositions containing such compounds. The present invention also provides a method of selectively activating an A3 adenosine receptor in a mammal, which method comprises acutely or chronically administering to a mammal in need of selective activation of its A3 adenosine receptor a therapeutically effective amount of a compound which binds with the A3 receptor so as to stimulate an A3 receptor-dependent response.
DE69428536T 1993-07-13 1994-07-13 A3 ADENOSINE RECEPTOR AGONISTS Expired - Lifetime DE69428536T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9110993A 1993-07-13 1993-07-13
US16332493A 1993-12-06 1993-12-06
PCT/US1994/007835 WO1995002604A1 (en) 1993-07-13 1994-07-13 A3 adenosine receptor agonists

Publications (2)

Publication Number Publication Date
DE69428536D1 DE69428536D1 (en) 2001-11-08
DE69428536T2 true DE69428536T2 (en) 2002-06-06

Family

ID=26783598

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69428536T Expired - Lifetime DE69428536T2 (en) 1993-07-13 1994-07-13 A3 ADENOSINE RECEPTOR AGONISTS

Country Status (6)

Country Link
US (1) US5773423A (en)
EP (1) EP0708781B1 (en)
AT (1) ATE206432T1 (en)
AU (1) AU7331094A (en)
DE (1) DE69428536T2 (en)
WO (1) WO1995002604A1 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
AU2603197A (en) 1996-04-10 1997-10-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of an a1 adenosine receptor agonist to treat cerebral ischaemia
GB9610031D0 (en) * 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
WO1998006855A1 (en) * 1996-08-16 1998-02-19 The Texas A & M University System Compositions and methods for delivery of nucleic acids to hepatocytes
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AU740770B2 (en) 1997-06-18 2001-11-15 Aderis Pharmaceuticals, Inc. Compositions and methods for preventing restenosis following revascularization procedures
US6110902A (en) * 1997-06-23 2000-08-29 Moehler; Hanns Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
YU44900A (en) 1998-01-31 2003-01-31 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CN1301167A (en) * 1998-06-15 2001-06-27 荷兰应用科学研究会(Tno) Treatment of organophosphate poisoning
AU750462B2 (en) 1998-06-23 2002-07-18 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2336967C (en) 1998-07-10 2010-06-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
CO5180581A1 (en) * 1999-09-30 2002-07-30 Pfizer Prod Inc COMPOUNDS FOR THE TREATMENT OF THE ISCHEMIA PHARMACEUTICAL TIONS THAT CONTAIN THEM FOR THE TREATMENT OF THE ISCHEMIA
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
AU3091301A (en) 2000-01-14 2001-07-24 Us Health Methanocarba cycloalkyl nucleoside analogues
US20010051348A1 (en) 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
AU2002219497B2 (en) * 2001-01-16 2004-08-26 Can-Fite Biopharma Ltd. Use of an adenosine A3 receptor agonist for inhibition of viral replication
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
EP1241176A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
JP2002338593A (en) * 2001-05-22 2002-11-27 Ajinomoto Co Inc Method of producing beta-d-ribofuranose derivative or optical isomer thereof
US6921594B2 (en) * 2001-12-19 2005-07-26 Sud-Chemie Inc. Exhaust treatment and filtration system for molten carbonate fuel cells
US6846988B2 (en) * 2002-01-18 2005-01-25 Adc Telecommunications, Inc. Triaxial connector including cable clamp
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
AU2003282359A1 (en) * 2002-11-19 2004-06-15 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
CZ294538B6 (en) * 2002-12-30 2005-01-12 Ústav Experimentální Botaniky Akademie Vědčeské Re Substituting derivatives of N6-benzyladenosine, process of their preparation, their use in the preparation of medicaments, cosmetic compositions and growth regulators, as well as pharmaceutical preparations, cosmetic compositions and growth regulators in which these compounds are comprised
US20050101560A1 (en) * 2003-11-12 2005-05-12 Can-Fite Biopharma Ltd. Method of treating an individual with methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl] beta-D-ibofuronamide
EP1699459B1 (en) * 2003-12-29 2007-06-06 Can-Fite Biopharma Ltd. Method for treatment of multiple sclerosis
AR049384A1 (en) 2004-05-24 2006-07-26 Glaxo Group Ltd PURINA DERIVATIVES
KR101167342B1 (en) 2004-05-26 2012-07-19 이노텍 파마슈티컬스 코포레이션 Purine derivatives as adenosine a1 receptor agonists and methods of use thereof
US7825102B2 (en) * 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
DK1778239T3 (en) * 2004-07-28 2013-12-02 Can Fite Biopharma Ltd ADENOSIN-A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASES CONNECTED WITH DRY EYES, INCLUDING SJÖGREN'S SYNDROME
US7825126B2 (en) * 2004-09-09 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services Purine derivatives as A3 and A1 adenosine receptor agonists
AU2005286946B2 (en) 2004-09-20 2012-03-15 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
US20080051364A1 (en) * 2004-11-08 2008-02-28 Pninna Fishman Therapeutic Treatment of Accelerated Bone Resorption
US20080070860A1 (en) * 2005-02-04 2008-03-20 Uti Limited Partnership Adenosine Analogs Useful as Anti-Bacterial and Anti Protozoan Agents
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
ATE540673T1 (en) * 2005-11-30 2012-01-15 Can Fite Biopharma Ltd USE OF A3 ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF OSTEOARTHRITIS
AU2006320578B2 (en) 2005-11-30 2013-01-31 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
EP2010534A4 (en) * 2006-04-13 2010-08-18 Astrazeneca Ab Thioxanthine derivatives and their use as inhibitors of mpo
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
US7893227B2 (en) * 2006-12-05 2011-02-22 Lasergen, Inc. 3′-OH unblocked nucleotides and nucleosides base modified with non-cleavable, terminating groups and methods for their use in DNA sequencing
WO2008111082A1 (en) * 2007-03-14 2008-09-18 Can-Fite Biopharma Ltd. Process for the synthesis of ib-meca
US8153781B2 (en) 2007-06-29 2012-04-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Dendrimer conjugates of agonists and antagonists of the GPCR superfamily
US8846635B2 (en) * 2007-10-15 2014-09-30 Can-Fite Biopharma Ltd. Method for inducing hepatocyte proliferation and uses thereof
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
ES2531828T3 (en) 2008-03-31 2015-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as selective agonists of adenosine A3 receptors
CN103588839B (en) 2008-06-11 2017-04-12 激光基因公司 Nucleotides and nucleosides and method for their use in DNA sequencing
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
JP5431476B2 (en) * 2008-08-01 2014-03-05 アメリカ合衆国 A3 adenosine receptor antagonist and A3 adenosine receptor partial agonist
CA2761499A1 (en) 2009-05-17 2010-11-25 Can-Fite Biopharma Ltd. A3 adenosine receptor agonists for the reduction of intraocular pressure
WO2011010306A1 (en) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US8518957B2 (en) 2009-12-02 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure
WO2011085361A1 (en) 2010-01-11 2011-07-14 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
CA2790869A1 (en) 2010-03-03 2011-09-09 Government Of The Usa, Represented By The Secretary, Department Of Healt H And Human Services A3ar agonists for the treatment of uveitis
US8476247B2 (en) 2010-03-26 2013-07-02 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
US20130165399A1 (en) * 2010-06-18 2013-06-27 Hayashibara Co., Ltd. Therapeutic agent for inflammatory diseases, containing adenosine n1-oxide as an effective ingredient
WO2012100654A1 (en) * 2011-01-26 2012-08-02 北京化工大学 Ribofuranosyl purine compound, preparation method therefor, and use thereof
CN102617680B (en) * 2011-02-01 2014-04-02 复旦大学 Bi-functional antiplatelet aggregation medicine and application thereof
DE102011005232A1 (en) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosine and its derivatives for use in pain therapy
EP3670523B1 (en) 2011-09-13 2021-08-11 Agilent Technologies, Inc. 3'-oh unblocked, fast photocleavable terminating nucleotides and their use in methods for nucleic acid sequencing
AU2013211957B2 (en) 2012-01-26 2017-08-10 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of (2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof
CN103421067A (en) * 2012-05-18 2013-12-04 复旦大学 Double-target drug for anti-platelet aggregation and applications thereof
MX2015001644A (en) 2012-08-09 2015-08-14 Can Fite Biopharma Ltd A3 adenosine receptor ligands for use in treatment of a sexual dysfunction.
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
JP2015172077A (en) * 2015-06-24 2015-10-01 中国医学科学院葯物研究所 Applications of n6-substituted adenosine derivative and n6-substituted adenine derivative to calming, hypnoses, convulsion resistance, epileptic resistance, parkinson disease resistance, and dementia prevention and treatment
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
WO2017185061A1 (en) * 2016-04-21 2017-10-26 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
CN106632333A (en) * 2016-11-30 2017-05-10 湖州恒远生物化学技术有限公司 Preparation method of low-cost 8-chlorotheophylline
IL254535A0 (en) 2017-09-17 2017-11-30 Can Fite Biopharma Ltd A3 adenosine receptor ligand for managing cytokine release syndrome
CN109666053A (en) * 2017-10-16 2019-04-23 张家口华健致远生物科技有限公司 A kind of A3 adenosine receptor agonist and application thereof
WO2019105388A1 (en) * 2017-11-29 2019-06-06 苏州科睿思制药有限公司 Crystal form of a3 adenosine receptor agonist drug, and preparation method therefor and use thereof
JP7311855B2 (en) 2018-02-09 2023-07-20 アストロサイト ファーマシューティカルズ， インコーポレイテッド Compounds and methods for treating addiction and related disorders
CN112930349A (en) 2018-09-26 2021-06-08 阿斯特罗赛特制药公司 Polymorphic compounds and uses thereof
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina An a3 adenosine receptor ligand for use for reducing level of adipocytes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6717061A (en) * 1966-12-21 1968-06-24
DE2524284A1 (en) * 1966-12-21 1976-10-28 Boehringer Mannheim Gmbh Cardiovascular-active nitrogen substd. adenosine derivs. - prepd. by reacting amines with 6-(halo or mercapto)-9-purinyl ribosides
US5310731A (en) * 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US5140015A (en) * 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage

Also Published As

Publication number Publication date
EP0708781A1 (en) 1996-05-01
WO1995002604A1 (en) 1995-01-26
US5773423A (en) 1998-06-30
EP0708781B1 (en) 2001-10-04
AU7331094A (en) 1995-02-13
ATE206432T1 (en) 2001-10-15
DE69428536D1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
ATE206432T1 (en) A3 -ADENOSINE RECEPTOR AGONISTS
DK0725782T3 (en) A1 adenosine receptor agonists and antiagonists
DE3880047T2 (en) COMPOSITION OF AN ADDITION.
IT8323205A0 (en) PHARMACEUTICAL COMPOSITIONS ANTI-INFLAMMATORY AND/OR ANALGESIC ADAPTIVITY, NON-ULCEROGENIC.
BR9612324A (en) "adenosine receptor agonists and antagonists a"
DK330789A (en) SUBSTITUTED 1,7-CANCELED 1 H INDAZOLES
DE69004256D1 (en) DIHYDROPYRIMIDINE ANTIALLERGY AGENT.
ES2134801T3 (en) CRYSTAL TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE.
HUP0103203A2 (en) Azaadamantane derivatives and pharmaceutical compositions thereof
DE3887839T2 (en) Release agent composition.
DE3852988T2 (en) Propylene-ethylene block copolymer composition.
DE3876490T2 (en) CORROSION-INHIBITING COMPOSITION.
NO943846L (en) Angiotensin II antagonists for disorders associated with impaired nerve conduction velocity, especially diabetic neuropathy
FI883673A0 (en) PHARMACEUTICAL COMPOSITION.
DK630589A (en) 2 ', 3'-DIDEOXYPURINNUCLEOSID / purine nucleoside phosphorylase inhibitor COMPOSITION
ES2106025T3 (en) SEMI-SYNTHETIC GANGLIOSIDE ANALOGS.
UA26443A (en) DERIVATIVES OF 20,21-DIHOROBURHAMECHIC, THEIR RACEMATES OR OPTICAL ISOMERS, OR THEIR ADDITIVE SALTS WITH ORGANIC ACIDS, WHICH MAY HAVE
DE69001580T2 (en) PERCUTANEOUS ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE.
DE69012388D1 (en) Selective adenosine receptor compounds.
DE68912159D1 (en) Antihypertensive agent containing dioxoquinazoline derivative.
NO892727D0 (en) SUSTAINABLE N-TERMINAL AMINODIOLAMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS.
ATE109483T1 (en) ALPHA ADRENEGIC RECEPTOR ANTAGONISTS.
ITTO920028A1 (en) STRUCTURALITY OF THE AUTOMOTIVE FRONT ARM SUPPORT.
ATE82138T1 (en) REGULATED ADMINISTRATION COMPOSITION.
NO882108L (en) BORE FLUSHING SYSTEM.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition